OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
The facility is based on a state-of-the-art design concept that allows maximum flexibility for a multi-product, multi-platform offering.
Aurigene Pharmaceutical Services, a contract research, development, and manufacturing organization (CDMO), announced on May 22, 2023 the construction of a state-of-the-art development and manufacturing facility for therapeutic proteins, antibodies, and viral vectors.
The first steps show Aurigene investing $40 million in an R&D and pilot-scale facility at Genome Valley, which is set to meet the process development and clinical supply needs of global biotech companies, according to a company press release. Further, the facility is based on a state-of-the-art design concept that allows maximum flexibility for a multi-product, multi-platform offering.
Set to be fully operational by 2024, the facility hopes to continue to be a strong presence in the biotherapeutics space, as it is complemented by exclusive access to an established large-scale good manufacturing practice (GMP) manufacturing facility with a drug substance capacity of 15kl and fill/finish capabilities. Additionally, another fill/finish line is under construction to be validated before the end of 2024, according to the press release.
“We see an increased outsourcing demand from global biopharmaceutical companies. With this expansion in biotherapeutics CDMO, we will be positioned to provide integrated services from clinical research to commercial manufacturing for small and large molecules,” said Akhil Ravi, CEO of Aurigene Pharmaceutical Services Ltd., in a press release. “Investing in emerging technologies and health solutions reinforces our aim to triple our existing reach to touch over 1.5 billion patients worldwide by 2030.”
Source: Aurigene Pharmaceutical Services